# Open-label Extension for Phase 3 Clinical Trials of Simufilam

> **NCT05575076** · PHASE3 · TERMINATED · sponsor: **Cassava Sciences, Inc.** · enrollment: 1081 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Simufilam

## Key facts

- **NCT ID:** NCT05575076
- **Lead sponsor:** Cassava Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-07
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 1081 (ACTUAL)
- **Why stopped:** sponsor decision
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05575076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05575076, "Open-label Extension for Phase 3 Clinical Trials of Simufilam". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05575076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*